Tipo di evidenza
Studio randomizzato sull’uomo
Direct recombinant growth-hormone randomized evidence
Pubblicazione e risultato principale
Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
In randomized paediatric studies, weekly PEGylated rhGH increased annualized height velocity to 13.41 cm per year and was non-inferior to daily rhGH, with comparable adverse-event rates.
European journal of endocrinology


